

Mark Kidd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3125823/publications.pdf>

Version: 2024-02-01

68
papers

8,345
citations

101543
36
h-index

102487
66
g-index

68
all docs

68
docs citations

68
times ranked

7082
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuroendocrine Tumor Omic Gene Cluster Analysis Amplifies the Prognostic Accuracy of the NETest. <i>Neuroendocrinology</i> , 2021, 111, 490-504.	2.5	14
2	Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest). <i>Annals of Surgical Oncology</i> , 2021, 28, 7506-7517.	1.5	25
3	Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy. <i>Annals of Surgery</i> , 2021, 274, 481-490.	4.2	22
4	Peptide radio receptor therapy: The huff and puff strategy of neuroendocrine disease management. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 19, 52-60.	1.4	0
5	A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy. <i>Endocrine-Related Cancer</i> , 2021, 28, 731-744.	3.1	9
6	Neuroendocrine Neoplasms of the Small Bowel and Pancreas. <i>Neuroendocrinology</i> , 2020, 110, 444-476.	2.5	70
7	An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis. <i>Neuroendocrinology</i> , 2020, 110, 198-216.	2.5	28
8	Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms. <i>Neuroendocrinology</i> , 2020, 110, 185-197.	2.5	14
9	The Use of Deep Learning and Neural Networks in Imaging: Welcome to the New Mathematical Milieu of Medicine. <i>Neuroendocrinology</i> , 2020, 110, 322-327.	2.5	5
10	The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. <i>Advances in Medical Sciences</i> , 2020, 65, 18-29.	2.1	38
11	Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis. <i>PLoS ONE</i> , 2019, 14, e0218592.	2.5	17
12	The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 631-639.	1.4	35
13	A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2018, 107, 73-90.	2.5	61
14	A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis. <i>Oncotarget</i> , 2018, 9, 7182-7196.	1.8	20
15	Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors. <i>Journal of Surgical Oncology</i> , 2018, 118, 37-48.	1.7	30
16	The NETest. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 485-504.	3.2	91
17	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. <i>Nature Genetics</i> , 2018, 50, 979-989.	21.4	168
18	Predicting the survival of patients with small bowel neuroendocrine tumours: comparison of 3 systems. <i>Endocrine Connections</i> , 2017, 6, 71-81.	1.9	25

#	ARTICLE	IF	CITATIONS
19	NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive. <i>Neuroendocrinology</i> , 2017, 104, 170-182.	2.5	87
20	Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms. <i>Journal of Thoracic Disease</i> , 2017, 9, S1458-S1473.	1.4	11
21	Chromogranin A. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 28-37.	2.3	55
22	Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 225-238.	4.6	97
23	A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. <i>Endocrine Connections</i> , 2016, 5, 174-187.	1.9	83
24	Minichromosome Maintenance Expression Defines Slow-Growing Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Translational Oncology</i> , 2016, 9, 411-418.	3.7	6
25	Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 691-705.	27.6	47
26	Myeloid neoplasms after chemotherapy and PRRT: myth and reality. <i>Endocrine-Related Cancer</i> , 2016, 23, C1-C7.	3.1	36
27	Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. <i>Surgery</i> , 2016, 159, 336-347.	1.9	90
28	Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. <i>Endocrine-Related Cancer</i> , 2015, 22, 561-575.	3.1	80
29	Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1437-E1445.	3.6	103
30	The Status of Neuroendocrine Tumor Imaging: From Darkness to Light?. <i>Neuroendocrinology</i> , 2015, 101, 1-17.	2.5	92
31	Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 5-19.	6.4	357
32	GNA15 expression in small intestinal neuroendocrine neoplasia: Functional and signalling pathway analyses. <i>Cellular Signalling</i> , 2015, 27, 899-907.	3.6	12
33	A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin,) <i>Tj ETQq1 1 0.784314 rgBT /Overlook</i>	3.1	93
34	Gut neuroendocrine tumor blood qPCR fingerprint assay: characteristics and reproducibility. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 419-429.	2.3	35
35	PRRT: Defining the Paradigm Shift to Achieve Standardization and Individualization. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1753-1756.	5.0	19
36	Recommendations for management of patients with neuroendocrine liver metastases. <i>Lancet Oncology</i> , The, 2014, 15, e8-e21.	10.7	413

#	ARTICLE	IF	CITATIONS
37	A Historical Appreciation of Bronchopulmonary Neuroendocrine Neoplasia. Thoracic Surgery Clinics, 2014, 24, 235-255.	1.0	5
38	Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors. BMC Genomics, 2014, 15, 595.	2.8	33
39	A mechanistic role for the chromatin modulator, NAP1L1, in pancreatic neuroendocrine neoplasm proliferation and metastases. Epigenetics and Chromatin, 2014, 7, 15.	3.9	50
40	Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors. Thoracic Surgery Clinics, 2014, 24, 333-349.	1.0	52
41	A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors. Endocrine Connections, 2014, 3, 215-223.	1.9	42
42	Neuroendocrine Tumor Biomarkers: Current Status and Perspectives. Neuroendocrinology, 2014, 100, 265-277.	2.5	75
43	Gastric Carcinoids (Neuroendocrine Neoplasms). Gastroenterology Clinics of North America, 2013, 42, 381-397.	2.2	27
44	The Identification of Gut Neuroendocrine Tumor Disease by Multiple Synchronous Transcript Analysis in Blood. PLoS ONE, 2013, 8, e63364.	2.5	139
45	Management of Gastric Carcinoids (Neuroendocrine Neoplasms). Current Gastroenterology Reports, 2012, 14, 467-472.	2.5	13
46	The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors. Endocrinology and Metabolism Clinics of North America, 2011, 40, 1-18.	3.2	715
47	Small intestinal neuroendocrine cell pathobiology: "carcinoid" tumors. Current Opinion in Oncology, 2011, 23, 45-52.	2.4	8
48	Chromogranin A "Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease. Annals of Surgical Oncology, 2010, 17, 2427-2443.	1.5	325
49	A Nomogram to Assess Small-Intestinal Neuroendocrine Tumor ("Carcinoid") Survival. Neuroendocrinology, 2010, 92, 143-157.	2.5	75
50	Delineation of the Chemomechanosensory Regulation of Gastrin Secretion Using Pure Rodent G Cells. Gastroenterology, 2009, 137, 231-241.e10.	1.3	33
51	Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors. Cancer, 2008, 112, 1404-1414.	4.1	32
52	Bronchopulmonary neuroendocrine tumors. Cancer, 2008, 113, 5-21.	4.1	439
53	Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer, 2008, 113, 690-700.	4.1	56
54	Neuroendocrine tumor epidemiology. Cancer, 2008, 113, 2655-2664.	4.1	464

#	ARTICLE	IF	CITATIONS
55	Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, G260-G272.	3.4	193
56	Neuroendocrine tumors of the diffuse neuroendocrine system. <i>Current Opinion in Oncology</i> , 2008, 20, 1-12.	2.4	140
57	Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin. <i>Journal of Molecular Endocrinology</i> , 2007, 38, 181-192.	2.5	47
58	GeneChip, geNorm, and gastrointestinal tumors: novel reference genes for real-time PCR. <i>Physiological Genomics</i> , 2007, 30, 363-370.	2.3	64
59	Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor- β -mediated regulatory abnormalities including up-regulation of c-Myc and MTA1. <i>Cancer</i> , 2007, 109, 2420-2431.	4.1	46
60	Gastrointestinal Carcinoids: The Evolution of Diagnostic Strategies. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 572-582.	2.2	110
61	Q RT-PCR Detection of Chromogranin A. <i>Annals of Surgery</i> , 2006, 243, 273-280.	4.2	31
62	The Role of Genetic Markers- NAP1L1, MAGE-D2, and MTA1- in Defining Small-Intestinal Carcinoid Neoplasia. <i>Annals of Surgical Oncology</i> , 2006, 13, 253-262.	1.5	108
63	Utility of molecular genetic signatures in the delineation of gastric neoplasia. <i>Cancer</i> , 2006, 106, 1480-1488.	4.1	34
64	Microsatellite instability and gene mutations in transforming growth factor- β type II receptor are absent in small bowel carcinoid tumors. <i>Cancer</i> , 2005, 103, 229-236.	4.1	74
65	A 5-decade analysis of 13,715 carcinoid tumors. <i>Cancer</i> , 2003, 97, 934-959.	4.1	2,478
66	Van Swieten and the Renaissance of the Vienna Medical School. <i>World Journal of Surgery</i> , 2001, 25, 444-450.	1.6	12
67	The pivotal role of John S. Edkins in the discovery of gastrin. <i>World Journal of Surgery</i> , 1997, 21, 226-234.	1.6	34
68	The History of the Pancreas. , 0, , 7-41.		3